Advanced/Metastatic Non-Small Cell Lung Cancer

Oncology·MeSH: Carcinoma, Non-Small-Cell Lung

Prevalence

75.0 / 100K

Incidence

47.0 / 100K/yr

8 drugs in development·5 companies·1 clinical trial

Drug Pipeline by Phase

Compare drugs

eftilagimod alfa vs tak-788eftilagimod alfa vs regn7075eftilagimod alfa vs sarilumab

Frequently asked questions

How many drugs are in development for Advanced/Metastatic Non-Small Cell Lung Cancer?

BioSniper tracks 8 drugs in development for Advanced/Metastatic Non-Small Cell Lung Cancer across 5 companies.

How many clinical trials target Advanced/Metastatic Non-Small Cell Lung Cancer?

There are 1 clinical trial targeting Advanced/Metastatic Non-Small Cell Lung Cancer tracked by BioSniper.

What is the prevalence of Advanced/Metastatic Non-Small Cell Lung Cancer?

The estimated prevalence of Advanced/Metastatic Non-Small Cell Lung Cancer is approximately 75.0 per 100,000 population.

Deep-dive into Advanced/Metastatic Non-Small Cell Lung Cancer

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Advanced/Metastatic Non-Small Cell Lung Cancer — Drugs in Development & Clinical Trials | BioSniper